Who
Mittie Doyle
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Avalo Therapeutics; Director, Cullinan Therapeutics; Director, DICE Therapeutics.
In numbers
- Trades disclosed
- 116
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $6.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 31 Mar 2022
- Last trade
- 28 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Aug 2026filed 1 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,459679 at $8.04 | filing |
| 28 Aug 2026filed 1 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K679 at $20.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —679 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —679 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,459679 at $8.04 | filing |
| 28 Aug 2026filed 1 Sep 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K679 at $20.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $13K1,000 at $12.65 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K1,000 at $20.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $13K1,000 at $12.65 | filing |
| 17 Aug 2026filed 19 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K1,000 at $20.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,459679 at $8.04 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K679 at $20.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —679 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —679 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $5,459679 at $8.04 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K679 at $20.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | $13K1,000 at $12.65 | filing |
| 27 Jul 2026filed 29 Jul 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K1,000 at $20.00 | filing |
News
Head-To-Head Survey: Avalo Therapeutics (NASDAQ:AVTX) & Ascendis Pharma A/S (NASDAQ:ASND)AVTX · themarketsdaily.com · 22 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) versus Praxis Precision Medicines (NASDAQ:PRAX) Financial AnalysisAVTX · tickerreport.com · 16 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Falls 6.6% – Should You Sell?AVTX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Mittie Doyle; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.